PhRMA Commends House of Representatives

Washington, D.C. (December 5, 2013) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matt Bennett issued the following statement on H.R. 3309, the Innovation Act, as passed by the U.S. House of Representatives today: 

“PhRMA commends the House of Representatives for its work to curb abusive patent litigation.

Transformative Technology to Treat Hepatitis C

12.05.13 | By

If you follow PhRMA and especially the Catalyst, you’ll notice we spend a lot of time focusing on how innovative medicines can be a great, transformative technology. A great example includes this morning’s NPR Morning Edition, reporting on new medicines to treat Hepatitis C, soon to be approved by the FDA. 

Clinical Trials in Alabama

12.05.13 | By

Biopharmaceutical research companies have already conducted more than 3,400 clinical trials of new medicines in Alabama since 1999.  And Governor Robert Bentley made clear yesterday his desire to see the valuable partnership between the biopharmaceutical sector and his state’s research institutions continue well into the future.

Implementing Responsible Clinical Trial Data Sharing

12.04.13 | By

Earlier this year, PhRMA member companies, along with member companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA), announced new commitments

Stopping Counterfeit Medicines Online

12.02.13 | By

Fake medicines put patients and the public at risk. In the U.S. almost all fake medicines enter the drug supply through purchases over the internet. This is a pervasive problem all around the world.

A Time to Give Thanks

11.22.13 | By

With Thanksgiving right around the corner, it’s a good opportunity to reflect on what we’re thankful for and the progress we’ve made this year. For the biopharmaceutical research companies discovering new medicines, we're proud of our advancements that have helped develop new treatments and ensured the health and safety of our patients.

Question Submission Form

PhRMA Innovation Act Letter

Early Detection for Prostate Cancer

11.19.13 | By

Prostate cancer is the second-most common form of cancer affecting men. In 2013, it is estimated that nearly 240,000 American men will be diagnosed with the disease and 29,000 will die from it.

PhRMA Statement: Drug Quality and Security Act

Washington, D.C. (November 18, 2013) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J Castellani issued the following statement:

“PhRMA is pleased that the Senate has passed the Drug Quality and Security Act and that the bill will now head to the White House for President Obama’s signature.


Subscribe to RSS - Opinion